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Haematopoietic stem cell transplantation is the only curative treatment for 
some forms of haematologcial malignancies and bone marrow failure.  The 
role of donor Natural Killer (NK) cells that accompany the donor stem cells is 
under investigation. In particular, there is interest in the role of the killer 
immunoglobulin-like receptors (KIR) family of receptors expressed on the 
surface receptors of NK cells. In this study, we focused on the donor KIR 
genes and the possibility that the KIR receptors interact with other transplant 
variables to influence survival. We analyzed a cohort of 140 unrelated donors 
from bone marrow transplants carried out at Royal Perth Hospital and 
Princess Margaret Hospital. The variables that were analyzed for interactions 
with KIR were: cytomegalovirus (CMV) status, transplant graft source, 
conditioning agents. A number of significant interactions between KIR and 
transplant variables were identified, the strongest being the interaction 
between KIR2DS2 and the use of cyclophosphamide as a conditioning agent. 
Kaplan-Meier analyses showed that the presence of KIR2DS2 in a 
cyclophosphamide positive transplant resulted in a significantly improved 
survival (p=0.002) whereas the presence of KIR2DS2 in a cyclophosphamide 
negative transplant resulted in a poorer survival (p=0.032). Hence the 
presence of KIR2DS2 could be beneficial or deleterious depending on the 
presence or absence of cyclophosphamide. As this was an exploratory study, 
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